Search

Your search keyword '"Myint, Zin W"' showing total 189 results
Start Over Author "Myint, Zin W"
189 results on '"Myint, Zin W"'

1. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, Cerbone, Linda, Seront, Emmanuel, Messina, Carlo, Molina-Cerrillo, Javier, Santini, Daniele, Yano, Akihiro, Incorvaia, Lorena, Catalano, Martina, Pinto, Alvaro, Formisano, Luigi, Soares, Andrey, Facchini, Gaetano, Fornarini, Giuseppe, Poprach, Alexandr, Rebuzzi, Sara Elena, Nasso, Cecilia, Spinelli, Gian Paolo, Angel, Martin, Stellato, Marco, Tural, Deniz, Aurilio, Gaetano, Epstein, Ilana, Carrozza, Francesco, Monteiro, Fernando Sabino Marques, Benedetti, Giovanni, Büchler, Tomáš, Ortega, Cinzia, Zakopoulou, Roubini, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquin, Gupta, Shilpa, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

Author

Santini, Daniele, Li, Haoran, Roviello, Giandomenico, Park, Se Hoon, Grande, Enrique, Kucharz, Jakub, Basso, Umberto, Fiala, Ondrej, Monteiro, Fernando Sabino Marques, Poprach, Alexandr, Buti, Sebastiano, Molina-Cerrillo, Javier, Catalano, Martina, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Myint, Zin W., Ghosn, Marwan, Calabrò, Fabio, Kopp, Ray Manneh, Bhuva, Dipen, Bourlon, Maria T., Roberto, Michela, Di Civita, Mattia Alberto, Mollica, Veronica, Marchetti, Andrea, Soares, Andrey, Battelli, Nicola, Ricci, Marco, Kanesvaran, Ravindran, Bamias, Aristotelis, Porta, Camillo, Massari, Francesco, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

3. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

Author

Rizzo, Alessandro, Buti, Sebastiano, Giannatempo, Patrizia, Salah, Samer, Molina-Cerrillo, Javier, Massari, Francesco, Kopp, Ray Manneh, Fiala, Ondřej, Galli, Luca, Myint, Zin W., Tural, Deniz, Soares, Andrey, Pichler, Renate, Mennitto, Alessia, Abahssain, Halima, Calabrò, Fabio, Monteiro, Fernando Sabino M., Albano, Anna, Mollica, Veronica, Giudice, Giulia Claire, Takeshita, Hideki, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

4. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

Author

Fiala, Ondřej, Buti, Sebastiano, Bamias, Aristotelis, Massari, Francesco, Pichler, Renate, Maruzzo, Marco, Grande, Enrique, De Giorgi, Ugo, Molina-Cerrillo, Javier, Seront, Emmanuel, Calabrò, Fabio, Myint, Zin W., Facchini, Gaetano, Kopp, Ray Manneh, Berardi, Rossana, Kucharz, Jakub, Vitale, Maria Giuseppa, Pinto, Alvaro, Formisano, Luigi, Büttner, Thomas, Messina, Carlo, Monteiro, Fernando Sabino M., Battelli, Nicola, Kanesvaran, Ravindran, Büchler, Tomáš, Kopecký, Jindřich, Santini, Daniele, Giudice, Giulia Claire, Porta, Camillo, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

5. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Author

Incorvaia, Lorena, Monteiro, Fernando Sabino Marques, Massari, Francesco, Park, Se Hoon, Roviello, Giandomenico, Fiala, Ondřej, Myint, Zin W., Kucharz, Jakub, Molina-Cerrillo, Javier, Santini, Daniele, Buttner, Thomas, Poprach, Alexandr, Kopecky, Jindrich, Zeppellini, Annalisa, Pichler, Martin, Buchler, Tomas, Pichler, Renate, Facchini, Gaetano, Fay, Andre Poisl, Soares, Andrey, Manneh, Ray, Iezzi, Laura, Kuronya, Zsofia, Russo, Antonio, Bourlon, Maria T., Bhuva, Dipen, Ansari, Jawaher, Kanesvaran, Ravindran, Grande, Enrique, Buti, Sebastiano, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

6. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Author

Massari, Francesco, Santoni, Matteo, Takeshita, Hideki, Okada, Yohei, Tapia, Jose Carlos, Basso, Umberto, Maruzzo, Marco, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Gandur, Nathalia, Lam, Elaine T., Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Kemp, Robert, Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Fiala, Ondřej, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino M., Dauster, Breno, Mennitto, Alessia, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Kopp, Ray Manneh, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchhorn, Daniel, Santini, Daniele, Bamias, Aristotelis, Bisonni, Renato, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Marchetti, Andrea, Rosellini, Matteo, Sorgentoni, Giulia, Battelli, Nicola, Buti, Sebastiano, Porta, Camillo, and Bellmunt, Joaquim

Published
2024
Full Text
View/download PDF

7. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Author

Massari, Francesco, Mollica, Veronica, Fiala, Ondrej, De Giorgi, Ugo, Kucharz, Jakub, Vitale, Maria Giuseppa, Molina-Cerrillo, Javier, Facchini, Gaetano, Seront, Emmanuel, Lenci, Edoardo, Bourlon, Maria T., Carrozza, Francesco, Pichler, Renate, Lolli, Cristian, Myint, Zin W., Kanesvaran, Ravindran, Torniai, Mariangela, Rescigno, Pasquale, Gomez de Liaño, Alfonso, Zakopoulou, Roubini, Buti, Sebastiano, Porta, Camillo, Grande, Enrique, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

8. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Author

Fiala, Ondřej, Buti, Sebastiano, Takeshita, Hideki, Okada, Yohei, Massari, Francesco, Palacios, Georgia Anguera, Dionese, Michele, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Quiroga, María Natalia Gandur, Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino Marques, Dauster, Breno, Cattrini, Carlo, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchenhorn, Daniel, Santini, Daniele, Manneh, Ray, Bisonni, Renato, Zakopoulou, Roubini, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquim, and Santoni, Matteo

Published
2023
Full Text
View/download PDF

9. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Author

Santoni, Matteo, Myint, Zin W., Büttner, Thomas, Takeshita, Hideki, Okada, Yohei, Lam, Elaine T., Gilbert, Danielle, Küronya, Zsófia, Tural, Deniz, Pichler, Renate, Grande, Enrique, Crabb, Simon J., Kemp, Robert, Massari, Francesco, Scagliarini, Sarah, Iacovelli, Roberto, Vau, Nuno, Basso, Umberto, Maruzzo, Marco, Molina-Cerrillo, Javier, Galli, Luca, Bamias, Aristotelis, De Giorgi, Ugo, Zucali, Paolo Andrea, Rizzo, Mimma, Seront, Emmanuel, Popovic, Lazar, Caffo, Orazio, Buti, Sebastiano, Kanesvaran, Ravindran, Kopecky, Jindrich, Kucharz, Jakub, Zeppellini, Annalisa, Fiala, Ondřej, Landmesser, Johannes, Ansari, Jawaher, Giannatempo, Patrizia, Rizzo, Alessandro, Zabalza, Ignacio Ortego, Monteiro, Fernando Sabino M., Battelli, Nicola, Calabrò, Fabio, and Porta, Camillo

Published
2023
Full Text
View/download PDF

10. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, and Porta, Camillo

Published
2023
Full Text
View/download PDF

11. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study

Author

Monteiro, Fernando Sabino Marques, Fiala, Ondřej, Massari, Francesco, Myint, Zin W., Kopecky, Jindrich, Kucharz, Jakub, Büttner, Thomas, Grande, Enrique, Bourlon, Maria Teresa, Molina-Cerrillo, Javier, Pichler, Renate, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Bamias, Aristotelis, Bhuva, Dipen, Vau, Nuno, Porta, Camillo, Fay, Andre Poisl, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

12. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johannes, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, and Porta, Camillo

Published
2024
Full Text
View/download PDF

15. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies

Author

Santoni, Matteo, Molina-Cerrillo, Javier, Myint, Zin W., Massari, Francesco, Buchler, Tomas, Buti, Sebastiano, Matrana, Marc R., De Giorgi, Ugo, Rizzo, Mimma, Zabalza, Ignacio Ortego, Galli, Luca, Zucali, Paolo Andrea, Aurilio, Gaetano, Incorvaia, Lorena, Bassanelli, Maria, Mammone, Giulia, Salfi, Alessia, Isella, Luca, Mollica, Veronica, Grande, Enrique, Porta, Camillo, and Battelli, Nicola

Published
2022
Full Text
View/download PDF

17. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, and Cerbone, Linda

Abstract

Background: Enfortumab vedotin (EV) has been approved for the treatment of patients with locally advanced/metastatic urothelial carcinoma (la/mUC) who previously received platinum-based chemotherapy followed by immune checkpoint inhibitors. However, the pivotal clinical trials did not include patients previously treated with avelumab maintenance therapy. Objective: The aim of the present retrospective analysis was to assess the effectiveness of EV following avelumab in patients with mUC enrolled in the ARON-2EV study. Patients and Methods: The study included 182 patients with mUC treated with EV following avelumab maintenance. The primary objective was to assess clinical outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and duration of response (DoR). Statistical analysis involved Fisher exact test, Kaplan–Meier method, log-rank test, and univariate/multivariate Cox proportional hazard regression models. Results: Median OS and PFS were 12.7 (95% CI 10.2–14.1) and 7.9 (95% CI 6.4–9.9) months, respectively. Complete response (CR) was achieved in 5% and partial response (PR) in 34% of patients, with an ORR of 39%. The DoR in patients who achieved CR/PR was 10.9 months (95% CI 8.1–11.4). The incidence of grade ≥ 3 peripheral neuropathy and skin rash was 9%, followed by 8% of grade ≥ 3 diarrhea and 4% of grade ≥ 3 hyperglycemia. Conclusions: The results of our large international retrospective study confirm the effectiveness of EV and endorse its use in the population of patients with mUC treated with EV following the frontline platinum-based chemotherapy and subsequent maintenance treatment with avelumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Salfi, Alessia, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Zakopoulou, Roubini, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Zampiva, Ilaria, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Catalini, Ilaria, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, Rizzo, Mimma, and Porta, Camillo

Published
2023
Full Text
View/download PDF

24. Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.

Author

Eule, Corbin J., Hu, Junxiao, Hedges, Dale, Jani, Alkesh, Pshak, Thomas, Manley, Brandon J., Sanchez, Alejandro, Dreicer, Robert, Myint, Zin W., Zakharia, Yousef, and Lam, Elaine T.

Subjects
CHRONIC kidney failure complications, RISK assessment, CREATININE, RESEARCH funding, CANCER patients, SYMPTOMS, DESCRIPTIVE statistics, MULTIVARIATE analysis, GENES, ODDS ratio, RENAL cell carcinoma, GENETIC mutation, OVERALL survival, DISEASE risk factors
Abstract

Simple Summary: Despite the increased risk of developing renal cell carcinoma (RCC) in patients with advanced chronic kidney disease (ACKD), little is known about the patient clinical characteristics and genetic mutations found in these RCC tumors. Using a multi-institutional research network, this study compiled clinical records and somatic tumor whole exome sequencing data of 296 adult patients with RCC, 61 of whom had ACKD. Patients with RCC and ACKD were more likely to be male, present with earlier stage RCC at diagnosis, and have lower rates of BAP1 mutations. Median overall survival was not reached in either group over a median follow-up of 31.3 months. These findings suggest RCC in patients with ACKD develops via a BAP1-independent mutational driver and further support BAP1 loss as a marker of disease aggressiveness. Background: Patients with advanced chronic kidney disease (ACKD) are at an increased risk of developing renal cell carcinoma (RCC), but molecular alterations in RCC specimens arising from ACKD and overall survival (OS) in affected patients are not well defined. Patients and Methods: Using the Oncology Research Information Exchange Network (ORIEN) Total Cancer Care® protocol, 296 consented adult patients with RCC and somatic tumor whole exome sequencing were included. Patients with ACKD were defined as those with serum creatinine ≥1.5 mg/dL prior to RCC diagnosis. Results: Of 296 patients with RCC, 61 met the criteria for ACKD. The most common somatic mutations in the overall cohort were in VHL (126, 42.6%), PBRM1 (102, 34.5%), and SETD2 (54, 18.2%). BAP1 had a decreased mutational frequency in RCC specimens from patients without ACKD as compared to those with ACKD (10.6% versus 1.6%), but this was not statistically significant in univariable (OR 0.14, p = 0.056) or multivariable (OR 0.15, p = 0.067) analysis. Median OS was not reached in either cohort. Conclusions: Using the clinicogenomic ORIEN database, our study found lower rates of BAP1 mutations in RCC specimens from patients with ACKD, which may reflect a BAP1-independent mutational driver of RCC in patients with ACKD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.

Author

Marques Monteiro, Fernando Sabino, Fiala, Ondřej, Massari, Francesco, Myint, Zin W., Kopecky, Jindrich, Kucharz, Jakub, Büttner, Thomas, Grande, Enrique, Bourlon, Maria Teresa, Molina-Cerrillo, Javier, Pichler, Renate, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Bamias, Aristotelis, Bhuva, Dipen, Vau, Nuno, Porta, Camillo, Fay, Andre Poisl, and Santoni, Matteo

Subjects
RENAL cell carcinoma, METASTASIS, BIOMARKERS, CANCER immunotherapy, KINASE inhibitors
Abstract

The treatment of metastatic renal cell carcinoma has evolved on last years. Nowadays immune-combinations are the standard treatment in first-line setting. There is no prognostic biomarker for metastatic renal cell carcinoma in the systemic immunotherapy treatment era. Systemic Immune-Inflammation Index is a cheap and readily available prognostic tool to be used in daily clinical practice. Background: Systemic treatment with immune combinations is the gold standard for metastatic renal cell carcinoma (mRCC) worldwide. The systemic immune-inflammation index (SII) is a prognostic marker for several types of malignant neoplasms, including mRCC, in the era of tyrosine kinase inhibitor (TKI) treatment. Data regarding the prognostic value of the SII in patients with mRCC treated with immunotherapy are scarce and controversial. Methods: We retrospectively collected the data of patients with mRCC from 56 centers in 18 countries. SII (Platelet × Neutrophil/Lymphocyte count) was calculated prior to the first systemic treatment and cut-off was defined by a survival receiver operating characteristic (ROC) analysis. The primary objective of our retrospective study was to assess the outcomes of patients treated with first-line immunotherapy. Results: Data from 1034 mRCC patients was collected and included in this analysis. The SII cut-off value was 1265. After a follow-up of 26.7 months, and the overall survival (OS) and progression-free survival (PFS) were 39.8 and 15.7 months, respectively. According to SII (low vs. high), patients with low-SII had longer OS (55.7 vs. 22.2 months, P < .001), better PFS (20.8 vs. 8.5 months, P < .001), and higher overall response rate (52 vs. 37%, P = .033). Conclusion: A high SII is associated with poor oncological outcomes in patients with mRCC. SII could be an easily accessible prognostic indicator for use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Systemic Immune-Inflammation Index in patients treated with first-line immune combinations for metastatic Renal Cell Carcinoma: insights from the ARON-1 study

Author

Monteiro, Fernando Sabino Marques, primary, Ondřej, Fiala, additional, Massari, Francesco, additional, Myint, Zin W., additional, Kopecky, Jindrich, additional, Kucharz, Jakub, additional, Büttner, Thomas, additional, Grande, Enrique, additional, Bourlon, Maria Teresa, additional, Molina-Cerrillo, Javier, additional, Pichler, Renate, additional, Buchler, Tomas, additional, Seront, Emmanuel, additional, Ansari, Jawaher, additional, Bamias, Aristotelis, additional, Bhuva, Dipen, additional, Vau, Nuno, additional, Porta, Camillo, additional, Fay, Andre Poisl, additional, and Santoni, Matteo, additional

Published
2023
Full Text
View/download PDF

29. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Author

PORTA, Camillo, primary, BAMIAS, Aristotelis, additional, ZAKOPOULOU, Roubini, additional, MYINT, Zin W., additional, CAVASIN, Nicolò, additional, IACOVELLI, Roberto, additional, PICHLER, Martin, additional, KOPECKY, Jindrich, additional, KUCHARZ, Jakub, additional, RIZZO, Mimma, additional, GALLI, Luca, additional, BÜTTNER, Thomas, additional, DE GIORGI, Ugo, additional, KANESVARAN, Ravindran, additional, FIALA, Ondřej, additional, GRANDE, Enrique, additional, ZUCALI, Paolo A., additional, KOPP, Ray M., additional, FORNARINI, Giuseppe, additional, BOURLON, Maria T., additional, SCAGLIARINI, Sarah, additional, MOLINA-CERRILLO, Javier, additional, AURILIO, Gaetano, additional, MATRANA, Marc R., additional, PICHLER, Renate, additional, CATTRINI, Carlo, additional, BÜCHLER, Tomáš, additional, MASSARI, Francesco, additional, MOLLICA, Veronica, additional, SERONT, Emmanuel, additional, CALABRÒ, Fabio, additional, PINTO, Alvaro, additional, BERARDI, Rossana, additional, ZGURA, Anca, additional, MAMMONE, Giulia, additional, ANSARI, Jawaher, additional, ATZORI, Francesco, additional, CHIARI, Rita, additional, CAFFO, Orazio, additional, PROCOPIO, Giuseppe, additional, SUNELA, Kaisa, additional, BASSANELLI, Maria, additional, ORTEGA, Cinzia, additional, GRILLONE, Francesco, additional, LANDMESSER, Johannes, additional, MERLER, Sara, additional, MESSINA, Carlo, additional, KÜRONYA, Zsófia, additional, MOSCA, Alessandra, additional, BHUVA, Dipen, additional, SANTINI, Daniele, additional, VAU, Nuno, additional, MORELLI, Franco, additional, INCORVAIA, Lorena, additional, REBUZZI, Sara E., additional, ROVIELLO, Giandomenico, additional, SOARES, Andrey, additional, ZABALZA, Ignacio O., additional, RIZZO, Alessandro, additional, BISONNI, Renato, additional, PIERANTONI, Francesco, additional, SORGENTONI, Giulia, additional, MONTEIRO, Fernando S., additional, BATTELLI, Nicola, additional, BUTI, Sebastiano, additional, and SANTONI, Matteo, additional

Published
2023
Full Text
View/download PDF

30. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, primary, Buti, Sebastiano, additional, Myint, Zin W., additional, Maruzzo, Marco, additional, Iacovelli, Roberto, additional, Pichler, Martin, additional, Kopecky, Jindrich, additional, Kucharz, Jakub, additional, Rizzo, Mimma, additional, Galli, Luca, additional, Büttner, Thomas, additional, De Giorgi, Ugo, additional, Kanesvaran, Ravindran, additional, Fiala, Ondřej, additional, Grande, Enrique, additional, Zucali, Paolo Andrea, additional, Kopp, Ray Manneh, additional, Fornarini, Giuseppe, additional, Bourlon, Maria T., additional, Scagliarini, Sarah, additional, Molina-Cerrillo, Javier, additional, Aurilio, Gaetano, additional, Matrana, Marc R., additional, Pichler, Renate, additional, Cattrini, Carlo, additional, Büchler, Tomas, additional, Massari, Francesco, additional, Seront, Emmanuel, additional, Calabrò, Fabio, additional, Pinto, Alvaro, additional, Berardi, Rossana, additional, Zgura, Anca, additional, Mammone, Giulia, additional, Ansari, Jawaher, additional, Atzori, Francesco, additional, Chiari, Rita, additional, Bamias, Aristotelis, additional, Caffo, Orazio, additional, Procopio, Giuseppe, additional, Sunela, Kaisa, additional, Bassanelli, Maria, additional, Ortega, Cinzia, additional, Grillone, Francesco, additional, Landmesser, Johannes, additional, Milella, Michele, additional, Messina, Carlo, additional, Küronya, Zsófia, additional, Mosca, Alessandra, additional, Bhuva, Dipen, additional, Santini, Daniele, additional, Vau, Nuno, additional, Morelli, Franco, additional, Incorvaia, Lorena, additional, Rebuzzi, Sara Elena, additional, Roviello, Giandomenico, additional, Soares, Andrey, additional, Bisonni, Renato, additional, Bimbatti, Davide, additional, Zabalza, Ignacio Ortego, additional, Rizzo, Alessandro, additional, Mollica, Veronica, additional, Sorgentoni, Giulia, additional, Monteiro, Fernando Sabino M., additional, Battelli, Nicola, additional, Bracarda, Sergio, additional, and Porta, Camillo, additional

Published
2023
Full Text
View/download PDF

31. Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience

Author

Myint, Zin W., McCormick, James, Chauhan, Aman, Behrens, Elizabeth, and Anthony, Lowell B.

Subjects
Hyperplasia -- Development and progression -- Prognosis -- Research, Health
Abstract

Background Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare pulmonary condition, characterized by diffuse proliferation of neuroendocrine cells in the respiratory epithelium. DIPNECH lesions are less than 5 mm in size and are limited to the basement membrane with no invasion. There is limited information regarding epidemiology, natural history of disease progression, or the management of this rare entity. We present the experience of a center with extensive expertise in neuroendocrine disease. Methods A cohort of patients (N = 13) with DIPNECH treated and followed at our institution was identified. We describe the our approach to their care, our disease management and also provide a review of DIPNECH pathophysiology. Results Our patient cohort consisted of twelve females and one male with a mean age of 63 years at the time of diagnosis. Dyspnea on exertion and dry cough were the most common presenting symptoms. Two patients were under surveillance without treatment; three patients were treated with a short-acting somatostatin analog; three patients were treated with azithromycin alone; four were treated with a combination of long-acting monthly somatostatin analogs and azithromycin; one patient received a combination of long-acting somatostatin analog and everolimus. Five patients had concomitant bronchial carcinoids. Conclusions DIPNECH is a rare pathology that can profoundly affect a patient's quality of life. Paroxysmal coughing episodes can be difficult to treat. Our limited single center experience shows encouraging response to use of somatostatin analogs, azithromycin, and everolimus in the management of debilitating DIPNECH associated symptoms., Author(s): Zin W. Myint [sup.1] , James McCormick [sup.2] , Aman Chauhan [sup.1] , Elizabeth Behrens [sup.3] , Lowell B. Anthony [sup.1] Author Affiliations: (Aff1) 0000 0004 1936 8438, grid.266539.d, [...]

Published
2018
Full Text
View/download PDF

34. A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer

Author

Myint, Zin W., primary, St. Clair, William H., additional, Strup, Stephen E., additional, Yan, Donglin, additional, Li, Ning, additional, Allison, Derek B., additional, McLouth, Laurie E., additional, Ellis, Carleton S., additional, Wang, Peng, additional, James, Andrew C., additional, Hensley, Patrick J., additional, Otto, Danielle E., additional, Arnold, Susanne M., additional, DiPaola, Robert S., additional, and Kolesar, Jill M., additional

Published
2023
Full Text
View/download PDF

36. Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Author

Rizzo, Alessandro, primary, Mollica, Veronica, additional, Marchetti, Andrea, additional, Nuvola, Giacomo, additional, Rosellini, Matteo, additional, Tassinari, Elisa, additional, Molina-Cerrillo, Javier, additional, Myint, Zin W., additional, Buchler, Tomas, additional, Monteiro, Fernando Sabino Marques, additional, Grande, Enrique, additional, Santoni, Matteo, additional, and Massari, Francesco, additional

Published
2022
Full Text
View/download PDF

42. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors

Author

Myint, Zin W., Momo, Harry D., Otto, Danielle E., Yan, Donglin, Wang, Peng, and Kolesar, Jill M.

Subjects
Male, Trauma Severity Indices, Antineoplastic Agents, Hormonal, Research, Incidence, Abiraterone Acetate, Prostatic Neoplasms, respiratory tract diseases, Tosyl Compounds, Online Only, Fractures, Bone, Oncology, Thiohydantoins, Risk Factors, Case-Control Studies, Benzamides, Nitriles, Phenylthiohydantoin, Androgen Receptor Antagonists, Humans, Pyrazoles, Accidental Falls, Anilides, Original Investigation
Abstract

Key Points Question What is the association between androgen receptor inhibitor (ARI) therapy and risk of fall and fracture in men with prostate cancer? Findings This systematic review and meta-analysis summarized the results of 11 eligible randomized clinical trials. Use of ARI (enzalutamide, apalutamide, or darolutamide) was associated with an increased risk for all-grade falls and factures, as well as grade 3 or greater falls and fracture. Meaning These findings suggest that patients who receive ARI therapy may have a higher risk of fall and fracture; this risk may need to be considered in cancer care., This systematic review and meta-analysis examines 11 randomized clinical trials to see whether therapy with androgen receptor inhibitors (ARIs), such as enzalutamide, apalutamide, or darolutamide, is associated with an increased risk of falls and fractures in men with prostate cancer., Importance A high incidence of fall and fracture in a subset of patients treated with androgen receptor inhibitors (ARIs) has been reported, although the relative risk (RR) of fall and fracture for patients who receive ARI treatment is unknown. Objective To evaluate whether treatment with ARIs is associated with an elevated relative risk for fall and fracture in patients with prostate cancer. Data Sources Cochrane, Scopus, and MedlinePlus databases were searched from inception through August 2019. Study Selection Randomized clinical trials comparing patients with prostate cancer treated with any ARI or placebo were included. Data Extraction and Synthesis Two independent reviewers used a standardized data extraction and quality assessment form. A mixed effects model was used to estimate the effects of ARI on relative risk, with included studies treated as random effects and study groups treated as fixed effects in the pooled analysis. Sample size for each study was used to weight the mixed model. Statistical analysis was performed from August to October 2019. Main Outcomes and Measures The primary outcome was RR of fall and fractures for patients receiving ARI treatment. Results Eleven studies met this study’s inclusion criteria. The total population was 11 382 men (median [range] age: 72 [43-97] years), with 6536 in the ARI group and 4846 in the control group. Participants in the ARI group could have received enzalutamide, apalutamide, or darolutamide in combination with androgen deprivation therapy or other enzalutamide combinations; patients in the control group could have received placebo, bicalutamide, or abiraterone. The reported incidence of fall was 525 falls (8%) in the ARI group and 221 falls (5%) in the control group. The incidence of fracture was 242 fractures (4%) in the ARI group and 107 fractures (2%) in the control group. Use of an ARI was associated with an increased risk of falls and fractures: all-grade falls (RR, 1.8; 95% CI, 1.42-2.24; P

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results